GNPTAB and hepatocellular carcinoma: Surprisingly, survival analysis showed that a higher gene expression level of LYSET/ATF4/VPS18/RAB7A/SLC7A5/TGFBRAP1/GNPTAB was associated with a significantly shorter OS in HBV-HCC patients (Figures 5B–H).